Name: Argenica Therapeutics (AGN) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

AGN

Pharmaceuticals, Biotechnology & Life Sciences

Argenica Therapeutics

Short interest: 0.01%; +0.01 pp 30d; as of 3 July 2026
Reported shorts: 15.2K
Shares on issue: 128.457M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Argenica Therapeutics

Argenica Therapeutics Limited is a biotechnology company focused on developing novel neuroprotective treatments aimed at reducing brain damage following strokes and other severe brain injuries. Positioned as an innovator in the neuroprotection field, the company leverages cutting-edge research to create therapies that can potentially transform patient outcomes.

Company profile →

Argenica Therapeutics (ASX:AGN) has 0.01% of its shares on issue reported as short positions as of 3 July 2026, or about 15,198 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. AGN is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads AGN today

Zanger BreakoutNot a candidate
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 6rank 1615 of 1716
Crowded-Short BreakoutNot a candidate
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

AGN fundamentals

In the year to 30 Jun 2026, Argenica Therapeutics (ASX:AGN) recorded revenue of A$212.0K and a net loss after tax of A$1.4M. A year earlier it recorded revenue of A$512.8K and a net loss after tax of A$7.2M. Year-on-year growth: revenue −58.7% (FY). Net margin −644.0% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →